MET and ovarian carcinoma: For example, upregulation of miR-34a-5p has been shown to suppress the malignant characteristics of ovarian cancer cells by targeting TRIM44, impeding the advancement of the disease (26).Additionally, the miR-34 family members exhibit co-targeting of MET, a receptor protein tyrosine kinase, which influences the motility and invasion of epithelial ovarian cancer (27).Research has identified that MET is a target of miR-34c, enhancing the anti-tumor efficacy of cisplatin in ovarian cancer cells (28).In a study by Lu et al.